Summary
Bristol-Myers Squibb Company (BMY) has filed an 8-K report on October 31, 2024, to announce its third-quarter 2024 financial results. The report primarily serves to furnish a press release detailing these results and a supplementary presentation that was made available during the company's earnings conference call. Investors should refer to the press release (Exhibit 99.1) for the specific financial and operational performance of the company during the third quarter. The company also notes that both the press release and the presentation contain non-GAAP financial information. Reconciliations of these non-GAAP measures to their nearest GAAP equivalents, along with explanations for their use, are provided within the furnished press release. Investors are advised to review these materials in conjunction with the press release to gain a comprehensive understanding of BMY's reported performance and strategic updates.
Key Highlights
- 1BMY filed an 8-K on October 31, 2024, to disclose third-quarter 2024 financial results.
- 2The filing includes a press release (Exhibit 99.1) detailing the Q3 2024 financial performance.
- 3A supplementary presentation (Exhibit 99.2) on financial and operating initiatives is also furnished.
- 4Both furnished documents include references to non-GAAP financial information.
- 5Reconciliations between non-GAAP and GAAP financial measures are available in the press release (Exhibit 99.1).
- 6The information furnished is not deemed 'filed' under Section 18 of the Exchange Act and does not carry the same liabilities.